Lung Cancer | Tumor

Lung Cancer Basics

October 25th 2017

Tips for Coping With Cancer: Make a "Grateful" List

October 14th 2015

Sometimes patients with cancer need to adjust their thinking to change how they view their disease

From Sickness to Health: A Matter of Declaration

October 14th 2015

Question: When do cancer scans shift from disease monitoring to routine checkups? Answer: You decide.

FDA Expands Opdivo Approval in Lung Cancer

October 9th 2015

The approval is based on data from the phase 3 CheckMate-057 trial, in which second-line Opdivo reduced the risk of death by 28 percent versus docetaxel in patients with nonsquamous NSCLC.

Keytruda Approved for Lung Cancer

October 3rd 2015

The PD-1 inhibitor was approved along with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, and is indicated for patients who progressed on or after platinum-containing chemotherapy or EGFR- or ALK-targeted agents in patients harboring those mutations.

Carolyn Presley on the Implications of Screening on Lung Cancer Care

October 3rd 2015

Carolyn Presley discusses the implications of screening on diagnosis and treatment of lung cancer.

Carolyn Presley Discusses the Burden of Curative Lung Cancer Treatment

October 3rd 2015

Carolyn Presley, clinical fellow, geriatric oncology, Yale Cancer Center, Robert Wood Johnson Clinical Scholar, discusses a study looking at the burden of health care on patients undergoing curative lung cancer care.

The Other Shoe

September 30th 2015

The stage 4 lung cancer life twists and turns down a bumpy road, but it is a road that I am lucky enough to still be traveling.

A View From a Young Lung Cancer Survivor: Genomic Testing Provides Hope

September 26th 2015

To gain a patient's perspective on the Genomics of Young Lung Cancer Study and the importance of genomic testing, we spoke with Corey Wood, a 23-year-old trial participant and lung cancer survivor.

Lecia V. Sequist on Side Effects From Agents for Resistant Lung Cancer

September 25th 2015

Lecia V. Sequist, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291).

Lecia V. Sequist Provides an Overview of T790M Mutations in NSCLC

September 24th 2015

Lecia V. Sequist, associate professor of medicine, Massachusetts General Hospital, provides an overview of T790M, a mutation in the epidermal growth factor receptor (EGFR) gene.

A Lung Cancer Diagnosis and the New Normal

September 22nd 2015

This is how my family and I were thrown into the cancer world.

Marianne Davies on Immunotherapy-Related Side Effects in Lung Cancer

September 21st 2015

Marianne Davies, from Smilow Cancer Hospital, Yale School of Nursing, provides an overview of immunotherapy-related side effects that patient with lung cancer may experience.

Survival Benefit With Opdivo Sustained in Squamous NSCLC

September 18th 2015

At an 18-month analysis, the overall survival rate with the PD-1 inhibitor was 28 percent versus 13 percent with docetaxel in previously treated patients with squamous NSCLC.

Gregory J. Riely on the Identification and Treatment of MET Exon 14 Skipping Mutations

September 15th 2015

Gregory J. Riely, associate attending physician, Memorial Sloan Kettering Cancer Center, discusses identifying and treating patients with MET exon 14 skipping mutations in lung cancer.

Small But Mighty: ROS1ers Unite

September 15th 2015

I have a rare mutation causing my cancer. Are there any others with ROS1 out there?

Gregory J. Riely on MET Exon 14 Skipping Mutations in Lung Cancer

September 14th 2015

Gregory J. Riely, associate attending physician, Memorial Sloan Kettering Cancer Center, provides an overview of MET exon 14 skipping mutations in lung cancer.

Adjuvant Avastin Does Not Improve Survival in NSCLC

September 12th 2015

The addition of Avastin (bevacizumab) to chemotherapy after initial therapy did not improve overall survival in patients with surgically resected early-stage non–small cell lung cancer.

April Hero Spotlight: Megan Pervier

September 11th 2015

My dad was diagnosed with Stage 4 lung cancer in February of 2014. His diagnosis included the BRAF mutation, which is still in the process of being researched for successful treatments.

Kim Statham Ringen on the Importance of Meeting Other Survivors

September 11th 2015

Kim Statham Ringen, DVM DACVIM (Oncology), a CURE contributor who is currently surviving stage 4 non-small cell lung cancer, discusses the importance of meeting other cancer survivors.

Kim Statham Ringen on the Stigma of Lung Cancer

September 11th 2015

Kim Statham Ringen, DVM DACVIM (Oncology), a CURE contributor who is currently surviving stage 4 non-small cell lung cancer, discusses the stigma of lung cancer.

Actionable Mutations Common in Lung Cancer Patients Under 40

September 10th 2015

Most patients younger than age 40 with lung cancer had tumors with mutations that can be targeted with existing therapies, according to a preliminary analysis of data from an ongoing study.

Pneumonitis: A Delayed Reaction

August 26th 2015

Pneumonitis, a lung inflammation, often appears months after the cancer treatment that sparked it.

Jyoti D. Patel on Treating Brain Metastases in Lung Cancer Patients

July 21st 2015

Jyoti D. Patel, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the treatment of patients with lung cancer with brain metastases.

Jyoti D. Patel on the Progress of Immunotherapy in NSCLC

July 21st 2015

Jyoti D. Patel, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the progress of immunotherapy as treatment for patients with non-small cell lung cancer.

E-cigarette Users Less Likely To Quit, Decrease Use Overall Versus Traditional Cigarette Smokers

May 12th 2015

E-cigarettes, championed by some as a smoking-cessation tool, may actually decrease the likelihood of quitting smoking, according to a recent population-based study of 1,000 smokers published in The American Journal of Public Health.

Finding Confidence in Community

May 8th 2015

It's incredible how much personality was squeezed into my mother's 4'10" frame. She was a spitfire. A burst of energy, starting friendly conversations with anyone and everyone she met.

The Phantom Scan

February 24th 2015

After nearly four years of cancer treatment, I thought I'd experienced all possible types of scanxiety. I was wrong.

Keytruda Granted Breakthrough Status for Lung Cancer

October 29th 2014

The FDA has granted a breakthrough therapy designation to the immunotherapy drug Keytruda (pembrolizumab) for the treatment of patients with non-small cell lung cancer.

Study Shows PARP Inhibitor Veliparib Could Help Patients with Squamous Cell Lung Cancer

October 27th 2014

Preliminary data from a phase 2 trial demonstrates that a combination of the PARP inhibitor veliparib and chemotherapy benefits patients with squamous cell non-small cell lung cancer.